Literature DB >> 15006970

Transforming growth factor-beta 1 and extracellular matrix-associated fibronectin expression in pulmonary lymphangioleiomyomatosis.

Scott E Evans1, Thomas V Colby, Jay H Ryu, Andrew H Limper.   

Abstract

STUDY
OBJECTIVES: Lymphangioleiomyomatosis (LAM) is a rare disorder of unknown etiology, affecting almost exclusively women of childbearing age, that is associated with the proliferation of spindle cells and cystic changes in the affected lung. The underlying processes that contribute to this disease are poorly understood. Transforming growth factor (TGF)-beta(1) is a potent cytokine that promotes mesenchymal cell proliferation and regulates the synthesis of extracellular matrix (ECM) components, particularly fibronectins. Herein, we evaluate the expression of TGF beta(1) and matrix-associated fibronectin in lung specimens demonstrating LAM.
DESIGN: Lung biopsy specimens that were confirmed to contain pathologic LAM cells were obtained from 13 patients. The specimens were submitted to immunohistochemical evaluation for TGF beta(1) and fibronectin, as well as the typical markers of LAM cells. Healthy lung parenchyma surrounding resected neoplasms was studied in a parallel fashion as control tissues. MEASUREMENTS AND
RESULTS: In all 13 LAM cases and in healthy lung parenchyma, we demonstrated that TGF beta(1) localized consistently to airway epithelial cells. However, in LAM tissues, matrix-associated TGF beta(1) was also consistently found in regions containing pathologic LAM cells. Notably, more abundant TGF beta(1) was observed in highly cellular areas compared to the walls of chronic cystic regions in LAM tissues. Fibronectin, a matrix component that is strongly expressed in response to active TGF beta(1) was found to consistently colocalize with this protein in these highly cellular regions, supporting TGF beta(1) activity in these regions. The markers of proliferating LAM cells, including proliferating cell nuclear antigen, were also markedly present in these highly cellular LAM regions.
CONCLUSION: These studies suggest that the proliferation of aberrant LAM cells may be associated with altered regional expression of TGF beta(1) and related ECM proteins.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15006970     DOI: 10.1378/chest.125.3.1063

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  8 in total

1.  NK cell activating receptor ligand expression in lymphangioleiomyomatosis is associated with lung function decline.

Authors:  Andrew R Osterburg; Rebecca L Nelson; Benyamin Z Yaniv; Rachel Foot; Walter Rf Donica; Madison A Nashu; Huan Liu; Kathryn A Wikenheiser-Brokamp; Joel Moss; Nishant Gupta; Francis X McCormack; Michael T Borchers
Journal:  JCI Insight       Date:  2016-10-06

2.  TSC2 modulates cell adhesion and migration via integrin-α1β1.

Authors:  Lyn M Moir; Judith L Black; Vera P Krymskaya
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-08-24       Impact factor: 5.464

3.  Angiotensin-converting enzyme inhibitors may affect pulmonary function in lymphangioleiomyomatosis.

Authors:  Wendy K Steagall; Mario Stylianou; Gustavo Pacheco-Rodriguez; Joel Moss
Journal:  JCI Insight       Date:  2019-03-07

4.  Vascular endothelial growth factors C and D induces proliferation of lymphangioleiomyomatosis cells through autocrine crosstalk with endothelium.

Authors:  Rachel B Issaka; Saji Oommen; Shiv K Gupta; Gang Liu; Jeffrey L Myers; Jay H Ryu; Nicholas E Vlahakis
Journal:  Am J Pathol       Date:  2009-08-28       Impact factor: 4.307

Review 5.  Targeting the airway smooth muscle for asthma treatment.

Authors:  Blanca Camoretti-Mercado
Journal:  Transl Res       Date:  2009-07-14       Impact factor: 7.012

6.  Lung epithelial cells are essential effectors of inducible resistance to pneumonia.

Authors:  J O Cleaver; D You; D R Michaud; F A Guzmán Pruneda; M M Leiva Juarez; J Zhang; P M Weill; R Adachi; L Gong; S J Moghaddam; M E Poynter; M J Tuvim; S E Evans
Journal:  Mucosal Immunol       Date:  2013-05-01       Impact factor: 7.313

7.  Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.

Authors:  Victoria Stepanova; Konstantin V Dergilev; Kelci R Holman; Yelena V Parfyonova; Zoya I Tsokolaeva; Mimi Teter; Elena N Atochina-Vasserman; Alla Volgina; Sergei V Zaitsev; Shane P Lewis; Fedor G Zabozlaev; Kseniya Obraztsova; Vera P Krymskaya; Douglas B Cines
Journal:  J Biol Chem       Date:  2017-09-27       Impact factor: 5.157

8.  A quantitative proteomic approach to identify significantly altered protein networks in the serum of patients with lymphangioleiomyomatosis (LAM).

Authors:  Nessa Banville; Janette K Burgess; Jade Jaffar; Gavin Tjin; Luca Richeldi; Stefania Cerri; Elisa Persiani; Judith L Black; Brian G Oliver
Journal:  PLoS One       Date:  2014-08-18       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.